Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 1, 1996, Pages 321-332

  Bourrié, Martine ^a   Meunier, Viviane ^a   Berger, Yves ^a   Fabre, Gérard ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; ANILINE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; DEXTRORPHAN; ETHOXYRESORUFIN; ETHOXYRESORUFIN DEETHYLASE; FURAFYLLINE; ISOENZYME; KETOCONAZOLE; NIFEDIPINE; OXIDOREDUCTASE; PARACETAMOL; PHENACETIN; PILOCARPINE; QUINIDINE; RESORUFIN; SULFAPHENAZOLE; TOLBUTAMIDE;

ARTICLE; ENZYME INACTIVATION; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

ADULT; AGED; ALLYL COMPOUNDS; CYTOCHROME P-450 ENZYME SYSTEM; DISULFIDES; FEMALE; HUMANS; ISOENZYMES; KETOCONAZOLE; MALE; MICROSOMES, LIVER; MIDDLE AGED; PILOCARPINE; QUINIDINE; SULFAPHENAZOLE;

EID: 0030430033     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. AND CHENERY, R. J.: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25: 261-270, 1995.
2. BIRKETT, D. J., MACKENZIE, P. I., VERONEZE, M. E. AND MINERS, J. O.: In vitro approaches can predict human drug metabolism. Trends Pharmacol. Sci. 14: 292-294, 1993.
3. BRADY, J. F., ISHISAKI, H., FUKUDO, J. M., LIN, M. C., FADEL, A., GAPAC, J. M. AND YUNG, C. S.: Inhibition of cytochrome P4502E1 by diallyldisulfide and its metabolites. Chem. Res. Toxicol. 4: 642-647, 1991.
4. BRØSEN, K., SKJELBO, E., RASMUSSEN, B. B., POULSEN, H. E. AND LOFT, S.: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45: 1211-1214, 1993.
5. BRIAN, W. R., SRIVASTAVA, P. K., UMBENHAUER, D. R., LLOYD, R. S. AND GUENGERICH, F. P.: Expression of a human liver cytochrome P450 protein with Tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28: 4993-4999, 1989.
6. BURKE, M. D., THOMPSON, S., ELCOMBE, C. R., HALPERT, J., HAAPARANTA, T. AND MAYER, R. T.: Ethoxy-, pentoxy-, and benzoyloxy-phenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34: 3337-3345, 1985.
7. BUTLER, M. A., IWASAKI, M., GUENGERICH, F. P. AND KADLUBAR, F. F.: Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarly responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines Proc. Natl. Acad. Sci. U.S.A. 86: 7696-7700, 1989.
8. CHANG, T. K. H., GONZALEZ, F. J. AND WAXMAN, D. J.: Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys 311: 437-442, 1994.
9. CHEN, L., LEE, M., HONG, J-Y., HUANG, W., WANG, E. AND YANG, C. S : Relationship between cytochrome P450 2E1 and acetone catabolism in rats as studied with diallyldisulfide as an inhibitor. Biochem. Pharmacol. 48: 2199-2205, 1994.
10. CHOLERTON, S., DALY, A. K. AND IDLE J. R.: The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci. 13: 434-439, 1992.
11. COMBALBERT, J., FABRE, I., FABRE, G., DALET, I., DERANCOURT, J., CANO, J. P. AND MAUREL, P.: Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (Cyclosporin A oxidase) as a product of P450 3A gene family. Drug Metab. Dispos. 17: 197-207, 1989.
12. CREAVEN, P. J., PARKE, D. V. AND WILLIAMS, R. T.: A spectrofluorimetric study of the 7-hydroxylation of coumarin by liver microsomes. Biochem. J. 96: 390-398, 1965.
13. DAUJAT, M., FABRE, I., DIAZ, D., PICHARD, L., FABRE, G., FABRE, J. M., SAINT-AUBERT, B. AND MAUREL, P.: Inducibility and expression of class IA and IIIA cytochromes P450 in primary cultures of adult human hepatocytes. Biochem. Pharmacol. (Life Sci. Adv.) 9: 315-326, 1990.
14. DISTLERATH, L. M., REILLY, P. E. B., MARTIN, M. V., DAVIS, G. G., WILKINSON, G. R. AND GUENGERICH, F. P.: Purification and characterization of the human cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 260: 9057-9067, 1985.
15. FABRE, G., CREVAT-PISANO, P., DRAGNA, S., COVO, J., BARRA, Y. AND CANO, J. P.: Involvement of the macrolide antibiotic cytochrome P450-LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. Biochem. Pharmacol. 37: 1947-1953, 1988.
16. FABRE, G., JULIAN, B., SAINT-AUBERT, B., JOYEUX, H. AND BERGER, Y.: Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab. Dispos. 21: 978-985, 1993.
17. GUENGERICH, F. P.: Characterization of human cytochrome P450 enzymes. FASEB J. 6: 745-748, 1992.
18. GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREMERS, P., WOLFF, T. AND WAXMAN, D. J.: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype of genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261: 5051-5060, 1986a.
19. GUENGERICH, F. P., MÜLLER-ENOCH, D. AND BLAIR, I. A.: Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30: 287-2995, 1986b.
20. GUENGERICH, F. P., KIM, D. H. AND IWASAKI, M.: Role of human cytochrome P-450 IIE1in the oxidation of may low molecular weight cancer suspects. Chem. Res. Toxicol. 4: 168-179, 1991
21. HALPERT, J. R., GUENGERICH, F. P., BEND, J R. AND CORREIA, M. A.: Comparative issues in toxicology: Selective inhibitors of cytochromes P450. Toxicol. Appl. Pharmacol. 125: 163-175, 1994.
22. KROMBACH, T., MATHYS, D., GUT, J , CATIN, T. AND MEYERS, U. A.: High performance liquid chromatography assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P450 isozymes of human liver. Anal. Biochem. 162: 24-32, 1987.
23. MAURICE, M., PICHARD, L., DAUJAT, M., FABRE, I., JOYEUX, H., DOMERGUE, J. AND MAUREL, P.: Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 6: 752-758, 1992.
24. MCKINNON, R. A., HALL, P. M., QUATTROCHI, L , TUKEY, R. H. AND MCMANUS, M E.: Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology 14: 848-852, 1991.
25. MINERS, M. O, SMITH, K. J., ROBSON, R. A., MCMANUS, M. E., VERONESE, M. E. AND BIRKETT, D. J.: Tolbutamide hydroxylation by human liver microsomes: Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 37: 1137-1144, 1988.
26. MINERS, M. O, VERONESE, M. E. AND BIRKETT, D. J.: In vitro approaches for the prediction of human drug metabolism. In Annual Reports in Medicinal Chemistry, ed. by J. A. Bristol, vol. 29, pp. 306-316, Academic Press, Inc., New York, 1994.
27. MIEYAL, J. J. AND BLUMER, J. L.: Acceleration of the autooxidation of human oxy hemoglobin by aniline and its relation to hemoglibin-catalyzed aniline hydroxylation. J. Biol. Chem. 251: 3442-3446, 1976.
28. NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., OKUDA, K. AND NEBERT, D. W.: The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12: 1-51, 1993.
29. NEBERT, D. J., WANG, R. W. AND LU, A. Y. H.: Cytochrome P450 inhibitors. Drug Metab. Dispos. 23: 154-158, 1995.
30. OMURA, T. AND SATO, R.: The carbon monoxide binding-pigment of liver microsomes: I. Evidence for its hemoprotein nature. J. Biol. Chem. 239: 2370-2378, 1964.
31. OTTON, S. V., INABA, T. AND KALOW, W.: Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular agents. Life Sci. 34: 73-80, 1984.
32. PELKONEN, O., SOTANIEMI, E. A. AND AHOKAS, J T.: Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and interspecies comparison. Br. J. Clin. Pharmacol. 19: 59-66, 1985.
33. PETER, R., BOCKER, R., BEAUNE, P. H. N., IWASAKI, M., GUENGERICH, F. P. AND YANG, C. S.: Hydroxylation of chlorzoxazone as a specific probe for human cytochrome P450IIE1. Chem. Res. Toxicol. 3: 566-573, 1990.
34. PICHARD, L., GILLET, G., FABRE, I., DALET-BELUCHE, I., BONFILS, C., THENOT, J. P. AND MAUREL, P.: Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab. Dispos. 18: 711-719, 1990.
35. POLLARD, H. B., MENARD, R., BRANDT, H. A., PAZOLZS, C. J., CREUTZ, C. E. AND RAMU, A.: Application of Bradford's protein assay to adrenal gland subcellular fractions. Anal. Biochem. 86: 761-763, 1978.
36. REINKE, L. A. AND MOYER, M. J.: p-Nitrophenol hydroxylation. A microsomal oxidation which is highly inducible by ethanol. Drug Metab. Dispos. 13: 548-552, 1985.
37. REMMEL, R. P. AND BURCHELL, B.: Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem. Pharmacol. 46: 559-566, 1993.
38. RODRIGUES, A. D.: Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem. Pharmacol. 48: 2147-2156, 1994.
39. SESARDIC, D., BOOBIS, A. R., EDWARDS, R. J. AND DAVIES, D. S: A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br. J. Clin. Pharmacol. 26: 363-372, 1988.
40. SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. AND DAVIES, D. S.: Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J. Clin. Pharmacol. 29: 651-663, 1990.
41. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. AND GUENGERICH, F. P.: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japaneses and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423, 1994.
42. STEARNS, R. A., CHAKRAVARTY, P. K., CHEN, R. AND CHIU, S-H. L.: Biotransformation of Losartan to its active carboxylic acid metabolite in human liver microsomes: Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos. 23: 207-215, 1995.
43. TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D J., GONZALEZ, F. J. AND MINERS, J. O.: Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA-expression and microsomal kinetic techniques. Biochem. Pharmacol. 46: 1975-1981, 1993.
44. TUCKER, G. T.: The rational selection of drug interaction studies; Implications of recent advances in drug metabolism. Int. J. Clin. Pharmacol. Ther. Toxicol. 30: 550-553, 1992.
45. WRIGHTON, S. A. AND RING, B. J.: Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketaconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharm. Res. 11: 921-924, 1994.
46. WRIGHTON, S. A. AND STEVENS, J. C.: The human hepatic cytochromes P460 involved in drug metabolism. Crit Rev. Toxicol. 22: 1-21, 1992.
47. YUN, C. H., SHIMADA, T. AND GUENGERICH, F. P.: Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol. 40: 679-685, 1991
48. YUN, C. H., LEE, H. S., LEE, H. Y., RHO, J. K., JEONG, H. G. AND GUENGERICH, F. P.: Oxidation of the angiotensin II receptor antagonist Losartan (DuP 753) in human liver microsomes; role of cytochrome P4503A(4) in formation of the active metabolite EXP 3174. Drug Metab. Dispos. 23: 285-289, 1995.